Ex vivo activated t-lymphocytic compositions and methods of using the same
AssigneeChildren's National Medical Center
InventorsCatherine Mary Bollard, Conrad Russell Y. Cruz, Patrick Hanley
Life of this patent
Estimating the term…
Abstract
The disclosure provides T-cell compositions, therapies and processes of manufacture that are tailored to the specific antigenic expression of a subjects' tumor and allowing for changes in expression over time based on either pressure from antineoplastic therapy or natural heterogeneous selection. The disclosure also extends to methods of manufacturing such T-cell compositions and the generation of single antigen T-cell banks from healthy donors to provide an improved personalized T-cell therapy.
Claims32
An isolated lymphocytic cell composition comprising about a fixed ratio of activated CD4+ T-cells, activated CD8+ T-cells, and activated CD3+ NKT-cells, wherein the CD4+ T-cells and CD8+ T-cells have been primed ex vivo against one or more tumor associated antigens (TAAs) or viral associated tumor antigens (VATAs), and wherein one or more of the activated CD4+ T-cells, activated CD8+ T-cells, and activated CD3+ NKT-cells comprise a fixed ratio of two or more separately primed and expanded cell subpopulations, each cell subpopulation having (i) specificity for a single tumor associated antigen and (ii) a different single tumor associated antigen specificity from all other cell subpopulations in the composition.
-4. (canceled)
-10. (canceled)
-17. (canceled)
-28. (canceled)
-154. (canceled)
An isolated lymphocytic cell composition comprising a fixed of activated αβ T-cells, activated γδ T-cells, and activated CD3+ NKT-cells,
- wherein the αβ T-cells have been primed ex vivo against two or more tumor associated antigens (TAAs) or viral associated tumor antigens (VATAs);
- wherein the αβ T-cells are comprised of two or more subpopulations;
- wherein each αβ T-cell subpopulation is specific for a single TAA or VATA;
- wherein each αβ T-cell subpopulation is specific for a different TAA or VATA than any another αβ T-cells subpopulation in the composition;
- and,
- wherein each of the αβ T-cell subpopulations are primed and expanded separately from each other.
-159. (canceled)
-163. (canceled)
-171. (canceled)
-174. (canceled)
-179. (canceled)
(canceled)
-189. (canceled)
Dependencies are inferred from the claim text.